Vascular permeability in cancer and infection as related to macromolecular drug delivery, with emphasis on the EPR effect for tumor-selective drug targeting

Proceedings of the Japan Academy Series B: Physical and Biological Sciences

Volumn 88, Issue 3, 2012, Pages 53-71

  Maeda, Hiroshi ^a  

^a SOJO UNIVERSITY   (Japan)

Author keywords

Enhanced permeability and retention (EPR) effect; Infection and cancer; Nanomedicine; Nitric oxide super oxide; Tumor targeted drug delivery; Vascular permeability

Indexed keywords

ANIMAL; CAPILLARY PERMEABILITY; DRUG DELIVERY SYSTEM; HUMAN; INFECTION; MACROMOLECULE; METABOLISM; METHODOLOGY; MOLECULARLY TARGETED THERAPY; NEOPLASM; REVIEW; VASCULARIZATION;

ANIMALS; CAPILLARY PERMEABILITY; DRUG DELIVERY SYSTEMS; HUMANS; INFECTION; MACROMOLECULAR SUBSTANCES; MOLECULAR TARGETED THERAPY; NEOPLASMS;

EID: 84860777658     PISSN: 03862208     EISSN: 13492896     Source Type: Journal    
DOI: 10.2183/pjab.88.53     Document Type: Review

References (100)

1. Matsumoto, K., Yamamoto, T., Kamata, R. and Maeda, H. (1984) Pathogenesis of serratial infection: activation of the Hageman factor-prekallikrein cascade by serratial protease. J. Biochem. 96, 739-749.
2. Kamata, R., Yamamoto, T., Matsumoto, K. and Maeda, H. (1985) A serratial protease causes vascular permeability reaction by activation of the Hageman factor-dependent pathway in guinea pigs. Infect. Immun. 48, 747-753.
3. Molla, A., Yamamoto, T., Akaike, T., Miyoshi, S. and Maeda, H. (1989) Activation of Hageman factor and prekallikrein and generation of kinin by various microbial proteinases. J. Biol. Chem. 264, 10589-10594.
4. Maruo, K., Akaike, T., Inada, Y., Ohkubo, I., Ono, T. and Maeda, H. (1993) Effect of microbial and mite proteases on low and high molecular weight kininogens. J. Biol. Chem. 268, 17711-17715.
5. Maeda, H. (2002) Microbial proteinases and pathogenesis of infection. In The Encyclopedia of Molecular Medicine, vol. 4 (ed. Creighton, T.E.). John Wiley & Sons, New York, pp. 2663-2668.
6. Maeda, H. (1996) Role of microbial proteases in pathogenesis. Microbiol. Immunol. 40, 685-699.
7. 3]-bradykinin in ascitic fluid from a patient with gastric cancer. J. Biol. Chem. 263, 16051-16054.
8. Matsumura, Y., Kimura, M., Yamamoto, T. and Maeda, H. (1988) Involvement of the kiningenerating cascade and enhanced vascular permeability in tumor tissue. Jpn. J. Cancer Res. 79, 1327-1334.
9. Matsumura, Y., Maruo, K., Kimura, M., Yamamoto, T., Konno, T. and Maeda, H. (1991) Kinin-generating cascade in advanced cancer patients and in vitro study. Jpn. J. Cancer Res. 82, 732-741.
10. Maeda, H., Wu, J., Okamoto, T., Maruo, K. and Akaike, T. (1999) Kallikrein-kinin in infection and cancer. Immunopharmacology 43, 115-128.
11. Maeda, H., Noguchi, Y., Sato, K. and Akaike, T. (1994) Enhanced vascular permeability in solid tumor is mediated by nitric oxide and inhibited by both new nitric oxide scavenger and nitric oxide synthase inhibitor. Jpn. J. Cancer Res. 85, 331-334.
12. Wu, J., Akaike, T., Hayashida, K., Okamoto, T., Okuyama, A. and Maeda, H. (2001) Enhanced vascular permeability in solid tumor involving peroxynitrite and matrix metalloproteinase. Jpn. J. Cancer Res. 92, 439-451.
13. Wu, J., Akaike, T. and Maeda, H. (1998) Modulation of enhanced vascular permeability in tumors by a bradykinin antagonist, a cyclooxygenase inhibitor, and a nitric oxide scavenger. Cancer Res. 58, 159-165.
14. Okamoto, T., Akaike, T., Nagano, T., Miyajima, S., Suga, M., Ando, M., Ichimori, K. and Maeda, H. (1997) Activation of human neutrophil procollagenase by nitrogen dioxide and peroxynitrite: a novel mechanism for procollagenase activation involving nitric oxide. Arch. Biochem. Biophys. 342, 261-274.
15. Maeda, H., Fang, J., Inutsuka, T. and Kitamoto, Y. (2003) Vascular permeability enhancement in solid tumor: various factors, mechanisms involved and its implications. Int. Immunopharmacol. 3, 319-328.
16. Maeda, H., Akaike, T., Wu, J., Noguchi, Y. and Sakata, Y. (1996) Bradykinin and nitric oxide in infectious disease and cancer. Immunopharmacology 33, 222-230.
17. Maeda, H., Takeshita, J. and Kanamaru, R. (1979) A lipophilic derivative of neocarzinostatin: A polymer conjugation of an antitumor protein antibiotic. Int. J. Pept. Protein Res. 14, 81-87.
18. Maeda, H., Ueda, M., Morinaga, T. and Matsumoto, T. (1985) Conjugation of poly(styrene-co-maleic acid) derivatives to the antitumor protein neocarzinostatin: Pronounced improvements in pharmacological properties. J. Med. Chem. 28, 455-461.
19. Iwai, K., Maeda, H. and Konno, T. (1984) Use of oily contrast medium for selective drug targeting to tumor: enhanced therapeutic effect and X-ray image. Cancer Res. 44, 2115-2121.
20. Iwai, K., Maeda, H., Konno, T., Matsumura, Y., Yamashita, R., Yamasaki, K., Hirayama, S. and Miyauchi, Y. (1987) Tumor targeting by arterial administration of lipids: rabbit model with VX2 carcinoma in the liver. Anticancer Res. 7, 321-328.
21. Courtice, F.C. (1996) The origin of lipoproteins in lymph. In Lymph and Lymphatic System (ed. Mayerson). Charles C Thomas Publisher, Springfield, IL, pp. 89-126.
22. Maeda, H., Takeshita, J. and Yamashita, A. (1980) Lymphotropic accumulation of an antitumor antibiotic protein, neocarzinostatin. Eur. J. Cancer 16, 723-731.
23. Takeshita, J., Maeda, H. and Kanamaru, R. (1982) In vitro mode of action, pharmacokinetics, and organ specificity of poly (maleic acid-styrene)-conjugated neocarzinostatin, SMANCS. Gann 73, 278-284.
24. Konno, T., Maeda, H., Iwai, K., Tashiro, S., Maki, S., Morinaga, T., Mochinaga, M., Hiraoka, T. and Yokoyama, I. (1983) Effect of arterial administration of high-molecular-weight anticancer agent SMANCS with lipid lymphographic agent on hepatoma: a preliminary report. Eur. J. Cancer Clin. Oncol. 19, 1053-1065.
25. Konno, T., Maeda, H., Iwai, K., Maki, S., Tashiro, S., Uchida, M. and Miyauchi, Y. (1984) Selective targeting of anticancer drug and simultaneous image enhancement in solid tumors by arterially administered lipid contrast medium. Cancer 54, 2367-2374.
26. Maki, S., Konno, T. and Maeda, H. (1985) Image enhancement in computerized tomography for sensitive diagnosis of liver cancer and semiquantitation of tumor selective drug targeting with oily contrast medium. Cancer 56, 751-757.
27. Matsumura, Y. and Maeda, H. (1986) A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent SMANCS. Cancer Res. 46, 6387-6392.
28. Noguchi, Y., Wu, J., Duncan, R., Strohalm, J., Ulbrich, K., Akaike, T. and Maeda, H. (1998) Early phase tumor accumulation of macromolecules: a great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 89, 307-314.
29. Seymour, L.W., Miyamoto, Y., Maeda, H., Brereton, M., Strohalm, J., Ulbrich, K. and Duncan, R. (1995) Influence of molecular weight on passive tumour accumulation of a soluble macromolecular drug carrier. Eur. J. Cancer 31, 766-770.
30. Maeda, H., Wu, J., Sawa, T., Matsumura, Y. and Hori, K. (2000) Tumor vascular permeability and the EPR effect in macromolecular therapeutics. J. Control. Release 65, 271-284.
31. Maeda, H., Sawa, T. and Konno, T. (2001) Mechanism of tumor-targeted delivery of macromolecular drugs, including the EPR effect in solid tumor and clinical overview of the prototype polymeric drug SMANCS. J. Control. Release 74, 47-61.
32. Maeda, H. (2001) The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. Adv. Enzyme Regul. 41, 189-207.
33. Maeda, H. and Matsumura, Y. (1989) Tumoritropic and lymphotropic principles of macromolecular drugs. Crit. Rev. Ther. Drug Carrier Syst. 6, 193-210.
34. Maeda, H., Bharate, G.Y. and Daruwalla, J. (2009) Polymeric drugs and nanomedicines for efficient tumor targeted drug delivery based on EPReffect. Eur. J. Pharm. Biopharm. 71, 409-419.
35. Maeda, H. (2010) Tumor-selective delivery of macromolecular drugs via the EPR effect: background and future prospects. Bioconjug. Chem. 21, 797-802.
36. Maeda, H. (2011) The EPR-effect in relation to tumor targeting. In Drug Delivery in Oncology. From Basic Research to Cancer Therapy (eds. Kratz, F., Senter, P. and Steinhagen, H.). Wiley-VCH Verlag GmbH & Co. KG, Weinheim, Germany, pp. 65-86.
37. Kimura, N., Taniguchi, S., Aoki, K. and Baba, T. (1980) Selective localization and growth of Bifidobacterium bifidum in mouse tumors following intravenous administration. Cancer Res. 40, 2061-2068.
38. Zhao, M., Yang, M., Li, X.M., Jiang, P., Baranov, E., Li, S., Xu, M., Penman, S. and Hoffman, R.M. (2005) Tumor-targeting bacterial therapy with amino acid auxotrophs of GFP-expressing Salmonella typhimurium. Proc. Natl. Acad. Sci. U.S.A. 102, 755-760.
39. Hoffman, R.M. (2009) Tumor-targeting amino acid auxotrophic Salmonella typhimurium. Amino Acids 37, 509-521.
40. Konerding, M.A., Miodonski, A.J. and Lametschwandtner, A. (1995) Microvascular corrosion casting in the study of tumor vascularity: a review. Scanning Microsc. 9, 1233-1244.
41. Hashizume, H., Baluk, P., Morikawa, S., McLean, J.W., Thurston, G., Roberge, S., Jain, R.K. and McDonald, D.M. (2000) Openings between defective endothelial cells explain tumor vessel leakiness. Am. J. Pathol. 1561, 1363-1380.
42. Skinner, S.A., Tutton, P.J. and O'Brien, P.E. (1990) Microvascular architecture of experimental colon tumors in the rat. Cancer Res. 50, 2411-2417.
43. Malcontenti-Wilson, C., Muralidharan, V., Skinner, S., Christophi, C., Sherris, D. and O'Brien, P.E. (2001) Combretastatin A4 prodrug study of effect on the growth and the microvasculature of colorectal liver metastases in a murine model. Clin. Cancer Res. 7, 1052-1060.
44. Daruwalla, J., Nikfarjam, M., Greish, K., Malcontenti-Wilson, C., Muralidharan, V., Christophi, C. and Maeda, H. (2010) In vitro and in vivo evaluation of tumor targeting styrenemaleic acid-pirarubicin micelles: survival improvement and inhibition of liver metastases. Cancer Sci. 101, 1866-1874.
45. Folkman, J. (1971) Tumor angiogenesis: therapeutic implications. N. Engl. J. Med. 285, 1182-1186.
46. Folkman, J. (1990) What is the evidence that tumors are angiogenesis dependent? J. Natl. Cancer Inst. 82, 4-6.
47. Folkman, J. (1995) Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat. Med. 1, 27-31.
48. Senger, D.R., Galli, S.J., Dvorak, A.M., Perruzzi, C.A., Harvey, V.S. and Dvorak, H.F. (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 219, 983-985.
49. Dvorak, H.F., Nagy, J.A., Dvorak, J.T. and Dvorak, A.M. (1988) Identification and characterization of the blood vessels of solid tumors that are leaky to circulating macromolecules. Am. J. Pathol. 133, 95-109.
50. Dvorak, H.F., Brown, L.F., Detmar, M. and Dvorak, A.M. (1995) Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 146, 1029-1039.
51. Leung, D.W., Cachianes, G., Kuang, W.J., Goeddel, D.V. and Ferrara, N. (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246, 1306-1309.
52. Miller, J.W., Adamis, A.P., Shima, D.T., D'Amore, P.A., Moulton, R.S., O'Reilly, M.S., Folkman, J., Dvorak, H.F., Brown, L.F., Berse, B., Yeo, T.K. and Yeo, K.T. (1994) Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am. J. Pathol. 145, 574-584.
53. Dvorak, H.F., Nagy, J.A., Feng, D., Brown, L.F. and Dvorak, A.M. (1999) Vascular permeability factor/vascular endothelial growth factor and the significance of microvascular hyperpermeability in angiogenesis. Curr. Top. Microbiol. Immunol. 237, 97-132.
54. Oda, T., Akaike, T., Hamamoto, T., Suzuki, F., Hirano, T. and Maeda, H. (1989) Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD. Science 244, 974-976.
55. - generation by xanthine oxidase of pathogenesis of influenza virus infection in mice. J. Clin. Invest. 85, 739-745.
56. Maeda, H. and Akaike, T. (1991) Oxygen free radicals as pathogenic molecules in viral diseases. Proc. Soc. Exp. Biol. Med. 198, 721-727.
57. Akaike, T., Noguchi, Y., Ijiri, S., Setoguchi, K., Suga, M., Zheng, Y.M., Dietzschold, B. and Maeda, H. (1996) Pathogenesis of influenza virus-induced pneumonia: involvement of both nitric oxide and oxygen radicals. Proc. Natl. Acad. Sci. U.S.A. 93, 2448-2453.
58. Akaike, T., Fujii, S., Kato, A., Yoshitake, J., Miyamoto, Y., Sawa, T., Okamoto, S., Suga, M., Asakawa, M., Nagai, Y. and Maeda, H. (2000) Viral mutation accelerated by nitric oxide production during infection in vivo. FASEB J. 14, 1447-1454.
59. Akaike, T. and Maeda, H. (2000) Pathophysiological effects of high-output production of nitric oxide. In Nitric Oxide (ed. Ignarro, L.J.). Academic Press, San Diego, pp. 733-745.
60. Akaike, T., Suga, M. and Maeda, H. (1998) Free radicals in viral pathogenesis: molecular mechanisms involving superoxide and NO. Proc. Soc. Exp. Biol. Med. 217, 64-73.
61. Umezawa, K., Akaike, T., Fujii, S., Suga, M., Setoguchi, K., Ozawa, A. and Maeda, H. (1997) Induction of nitric oxide synthesis and xanthine oxidase and their role in the antimicrobial mechanism against Salmonella typhimurium in mice. Infect. Immun. 65, 2932-2940.
62. Yoshitake, J., Akaike, T., Akuta, T., Tamura, F., Ogura, T., Esumi, H. and Maeda, H. (2004) Nitric oxide as an endogenous mutagen for Sendai virus without antiviral activity. J. Virol. 78, 8709-8719.
63. Doi, K., Akaike, T., Horie, H., Noguchi, Y., Fujii, S., Beppu, T., Ogawa, M. and Maeda, H. (1996) Excessive production of nitric oxide in rat solid tumor and its implication in rapid tumor growth. Cancer 77, 1598-1604.
64. Kuwahara, H., Kanazawa, A., Wakamatsu, D., Morimura, S., Kida, K., Akaike, T. and Maeda, H. (2004) Antioxidative and antimutagenic activities of 4-vinyl-2,6-dimethoxyphenol (canolol) isolated from canola oil. J. Agric. Food Chem. 52, 4380-4387.
65. Kuwahara, H., Kariu, T., Fang, J. and Maeda, H. (2009) Generation of drug-resistant mutants of Helicobacter pylori in the presence of peroxynitrite, a derivative of nitric oxide at pathophysiological concentration. Microbiol. Immunol. 53, 1-7.
66. Sawa, T. and Oshima, H. (2006) Nitrative DNA damage in inflammation and its possible role in carcinogenesis. Nitric Oxide 14, 91-100.
67. Niles, J.C., Wishnok, J.S. and Tannenbaum, S.R. (2006) Peroxynitrite-induced oxidation and nitration products of guanine and 8-oxoguanine: structures and mechanisms of product formation. Nitric Oxide 14, 109-121.
68. 5 reductase in the presence of NADH. Cancer Lett. 143, 117-121.
69. Sjöblom, T., Jones, S., Wood, L., Parsons, D.W., Lin, J., Barber, T.D., Mandelker, D., Leary, R.J., Ptak, J., Silliman, N., Szabo, S., Buckhaults, P., Farrell, C., Meeh, P., Markowitz, S.D., Willis, J., Dawson, D., Willson, J.K.V., Gazdar, A.F., Hartigan, J., Wu, L., Liu, C., Parmigiani, G., Park, B.H., Bachman, K.E., Papadopoulos, N., Vogelstein, B., Kinzler, K.W. and Velculescu, V.E. (2006) The consensus coding sequences of human breast and colorectal cancers. Science 314, 268-274.
70. Wood, L.D., Parsons, D.W., Jones, S., Lin, J., Sjöblom, T., Leary, R.J., Shen, D., Boca, S.M., Barber, T., Ptak, J., Silliman, N., Szabo, S., Dezso, Z., Ustyanksky, V., Nikolskaya, T., Nikolsky, Y., Karchin, R., Wilson, P.A., Kaminker, J.S., Zhang, Z., Croshaw, R., Willis, J., Dawson, D., Shipitsin, M., Willson, J.K.V., Sukumar, S., Polyak, K., Park, B.H., Pethiyagoda, C.L., Pant, P.V.K., Ballinger, D.G., Sparks, A.B., Hartigan, J., Smith, D.R., Suh, E., Papadopoulos, N., Buckhaults, P., Markowitz, S.D., Parmigiani, G., Kinzler, K.W., Velculescu, V.E. and Vogelstein, B. (2007) The genomic landscapes of human breast and colorectal cancers. Science 318, 1108-1113.
71. Shah, S.P., Morin, R.D., Khattra, J., Prentice, L., Pugh, T., Burleigh, A., Delaney, A., Gelmon, K., Guliany, R., Senz, J., Steidl, C., Holt, R.A., Jones, S., Sun, M., Leung, G., Moore, R., Severson, T., Taylor, G.A., Teschendorff, A.E., Tse, K., Turashvili, G., Varhol, R., Warren, R.L., Watson, P., Zhao, Y., Caldas, C., Huntsman, D., Hirst, M., Marra, M.A. and Aparicio, S. (2009) Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution. Nature 461, 809-813.
72. Fojo, T. and Grady, C. (2009) How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J. Natl. Cancer Inst. 101, 1044-1048.
73. Mayer, R. (2009) Targeted therapy for advanced colorectal cancer-more is not always better. N. Engl. J. Med. 360, 623-625.
74. Anonymous (2008) Welcome clinical leadership at NICE. Lancet 372, 601.
75. Tol, J., Koopman, M., Cats, A., Rodenburg, C.J., Creemers, G.J.M., Schrama, J.G., Erdkamp, F.L.G., Vos, A.H., van Groeningen, C.J., Sinnige, H.A.M., Richel, D.J., Voest, E.E., Dijkstra, J.R., Vink-Börger, M.E., Antonini, N.F., Mol, L., van Krieken, J.H.J.M., Dalesio, O. and Punt, C.J.A. (2009) Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N. Engl. J. Med. 360, 563-572.
76. Kano, M.R., Bae, Y., Iwata, C., Morishita, Y., Yashiro, M., Oka, M., Fujii, T., Komuro, A., Kiyono, K., Kaminishi, M., Hirakawa, K., Ouchi, Y., Nishiyama, N., Kataoka, K. and Miyazono, K. (2007) Improvement of cancer-targeting therapy, using nanocarriers for intractable solid tumors by inhibition of TGF-β signaling. Proc. Natl. Acad. Sci. U.S.A. 104, 3460-3465.
77. Huang, S., Robinson, J.B., Deguzman, A., Bucana, C.D. and Fidler, I.J. (2000) Blockade of nuclear factor-κB signaling inhibits angiogenesis and tumorigenicity of human ovarian cancer cells by suppressing expression of vascular endothelial growth factor and interleukin 8. Cancer Res. 60, 5334-5339.
78. 2 analogue beraprost sodium. J. Drug Target. 11, 45-52.
79. Doi, K., Akaike, T., Fujii, S., Tanaka, S., Ikebe, N., Beppu, T., Shibahara, S., Ogawa, M. and Maeda, H. (1999) Induction of haem oxygenase-1 by nitric oxide and ischaemia in experimental solid tumours and implications for tumour growth. Br. J. Cancer 80, 1945-1954.
80. Fang, J., Qin, H., Nakamura, H., Tsukigawa, K. and Maeda, H. (2012) Carbon monoxide, generated by heme oxygenase-1, mediates the enhanced permeability and retention (EPR) effect of solid tumor. Cancer Sci. 103 (in press available online, Jan. 2012).
81. Sahoo, S.K., Sawa, T., Fang, J., Tanaka, S., Miyamoto, Y., Akaike, T. and Maeda, H. (2002) Pegylated zinc protoporphyrin: a water-soluble heme oxygenase inhibitor with tumor-targeting capacity. Bioconjug. Chem. 13, 1031-1038.
82. Fang, J., Sawa, T., Akaike, T., Akuta, T., Greish, K., Hamada, A. and Maeda, H. (2003) In vivo antitumor activity of pegylated zinc protoporphyrin: targeted inhibition of heme oxygenase in solid tumor. Cancer Res. 63, 3567-3574.
83. Fang, J., Akaike, T. and Maeda, H. (2004) Antiapoptotic role of heme oxygenase and its potential as an anticancer target. Apoptosis 9, 27-35.
84. Daruwalla, J., Greish, K., Wilson, C.M., Muralidharan, V., Iyer, A., Maeda, H. and Christophi, C. (2009) Styrene maleic acid-pirarubicin disrupts tumor microcirculation and enhances the permeability of colorectal liver metastases. J. Vasc. Res. 46, 218-228.
85. Suzuki, M., Hori, K., Abe, I., Saito, S. and Sato, H. (1981) A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J. Natl. Cancer Inst. 67, 663-669.
86. Hori, K., Suzuki, M., Tanda, S., Saito, S., Shinozaki, M. and Zhang, Q.H. (1991) Fluctuations in tumor blood flow under normotension and the effect of angiotensin II-induced hypertension. Jpn. J. Cancer Res. 82, 1309-1316.
87. Li, C.J., Miyamoto, Y., Kojima, Y. and Maeda, H. (1993) Augmentation of tumour delivery of macromolecular drugs with reduced bone marrow delivery by elevating blood pressure. Br. J. Cacner 67, 975-980.
88. Nagamitsu, A., Greish, K. and Maeda, H. (2009) Elevating blood pressure as a strategy to increase tumor targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn. J. Clin. Oncol. 39, 756-766.
89. Seki, T., Fang, J. and Maeda, H. (2009) Enhanced delivery of macromolecular antitumor drugs to tumors by nitroglycerin application. Cancer Sci. 100, 2426-2430.
90. Maeda, H. (2010) Nitroglycerin enhances vascular blood flow and drug delivery in hypoxic tumor tissues: analogy between angina pectoris and solid tumors and enhancement of the EPR effect. J. Control. Release 142, 296-298.
91. Feelisch, M. and Noack, E. (1987) Correlation between nitric oxide formation during degradation of organic nitrates and activation of guanylate cyclase. Eur. J. Pharmacol. 139, 19-30.
92. Fukuto, J.M., Cho, J.Y. and Switzer, C.H. (2000) The chemical properties of nitric oxide and related nitrogen oxides. In Nitric Oxide: Biology and Pathobiology (ed. Ignarro, L.J.). Academic Press, San Diego, pp. 23-39.
93. Mitchell, J.B., Wink, D.A., DeGraff, W., Gamson, J., Keefer, L.K. and Krishna, M.C. (1993) Hypoxic mammalian cell radiosensitization by nitric oxide. Cancer Res. 53, 5845-5848.
94. Yasuda, H., Yamaya, M., Nakayama, K., Sasaki, T., Ebihara, S., Kanda, A., Asada, M., Inoue, D., Suzuki, T., Okazaki, T., Takahashi, H., Yoshida, M., Kaneta, T., Ishizawa, K., Yamanda, S., Tomita, N., Yamasaki, M., Kikuchi, A., Kubo, H. and Sasaki, H. (2006) Randomized phase II trial comparing nitroglycerin plus vinorelbine and cisplatin with vinorelbine and cisplatin alone in previously untreated stage IIIB/IV non-small cell lung cancer. J. Clin. Oncol. 24, 688-694.
95. Yasuda, H., Nakayama, K., Watanabe, M., Suzuki, S., Fuji, H., Okinaga, S., Kanda, A., Zayazu, K., Sasaki, T., Asada, M., Suzuki, T., Yoshida, M., Yamanda, S., Inoue, D., Kaneta, T., Kondo, T., Takai, Y., Sasaki, H., Yanagihara, K. and Yamaya, M. (2006) Nitroglycerin treatment may increase response to docetaxel and carboplatin regimen via inhibitions of hypoxia-inducible factor-1 pathway and P-glycoprotein in patients with lung adenocarcinoma. Clin. Cancer Res. 12, 6748-6757.
96. Yasuda, H., Yanagihara, K., Nakayama, K., Mio, T., Sasaki, T., Asada, M., Yamaya, M. and Fukushima, M. (2010) Therapeutic applications of nitric oxide for malignant tumor in animal models and human studies. In Nitric Oxide and Cancer (ed. Bonavida, B.). Springer Science, New York, pp. 419-441.
97. Siemens, D.R., Heaton, J.P.W., Adams, M.A., Kawakami, J. and Graham, C.H. (2009) Phase II study of nitric oxide donor for men with increasing prostate-specific antigen level after surgery or radiotherapy for prostate cancer. Urology 74, 878-883.
98. Jordan, B.F., Misson, P.D., Remeure, R., Baudelet, C., Beghein, N. and Gallez, B. (2000) Changes in tumor oxygenation/perfusion induced by the no donor, isosorbide dinitrate, in comparison with carbogen: monitoring by EPR and MRI. Int. J. Radiat. Oncol. Biol. Phys. 48, 565-570.
99. Noguchi, A., Takahashi, T., Yamaguchi, T., Kitamura, K., Noguchi, A., Tsurumi, H., Takashina, K. and Maeda, H. (1992) Enhanced tumor localization of monoclonal antibody by treatment with kininase II inhibitor and angiotensin II. Jpn. J. Cancer Res. 83, 240-243.
100. Hori, K., Saito, S., Takahashi, H., Sato, H., Maeda, H. and Sato, Y. (2000) Tumor-selective blood flow decrease induced by an angiotensin converting enzyme inhibitor, temocapril hydrochloride. Jpn. J. Cancer Res. 91, 261-269.